Marker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study

We recently published 10 Stocks Losing Big. Marker Therapeutics, Inc. (NASDAQ:MRKR) is one of the worst performers of Tuesday.

Marker Therapeutics dropped for a second day on Tuesday, slashing 20.63 percent to close at $1 as investors sold off amid the lack of fresh catalysts to sustain buying appetite.

On Monday, Marker Therapeutics, Inc. (NASDAQ:MRKR) earned a boost from promising results from the first phase study of its experimental treatment for lymphoma patients.

Called the Apollo study, Marker Therapeutics, Inc. (NASDAQ:MRKR) said that its multi-antigen recognizing T cell therapy registered an objective response rate of 66 percent in patients with Non-Hodgkin Lymphoma (NHL), with 50 percent achieving complete responses.

A total of 24 patients were enrolled in the clinical study, with 15 patients having NHL, while the other 9 had HL.

“We are very excited and encouraged by the progress of the study,” said Marker Therapeutics, Inc. (NASDAQ:MRKR) President and CEO Juan Vera.

“We believe that MT-601 could address this critical unmet need and offer new hope to patients who have exhausted multiple lines of treatment, including CAR-T cell therapy,” he noted.

While we acknowledge the potential of MRKR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.